As of 2025-07-04, the EV/EBITDA ratio of Protagonist Therapeutics Inc (PTGX) is 96.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PTGX's latest enterprise value is 3,002.11 mil USD. PTGX's TTM EBITDA according to its financial statements is 31.04 mil USD. Dividing these 2 quantities gives us the above PTGX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 12.8x | 12.6x |
| Forward P/E multiples | 20.6x - 43.4x | 32.0x |
| Fair Price | 8.46 - 22.62 | 12.92 |
| Upside | -83.3% - -55.4% | -74.5% |
| Date | EV/EBITDA |
| 2025-07-01 | 95.75 |
| 2025-06-30 | 105.86 |
| 2025-06-27 | 106.69 |
| 2025-06-26 | 105.75 |
| 2025-06-25 | 104.20 |
| 2025-06-24 | 102.68 |
| 2025-06-23 | 102.04 |
| 2025-06-20 | 102.00 |
| 2025-06-18 | 103.16 |
| 2025-06-17 | 105.74 |
| 2025-06-16 | 104.64 |
| 2025-06-13 | 108.05 |
| 2025-06-12 | 107.95 |
| 2025-06-11 | 106.00 |
| 2025-06-10 | 108.05 |
| 2025-06-09 | 106.67 |
| 2025-06-06 | 104.08 |
| 2025-06-05 | 102.96 |
| 2025-06-04 | 98.39 |
| 2025-06-03 | 97.45 |
| 2025-06-02 | 95.63 |
| 2025-05-30 | 90.28 |
| 2025-05-29 | 90.50 |
| 2025-05-28 | 86.85 |
| 2025-05-27 | 88.21 |
| 2025-05-23 | 86.67 |
| 2025-05-22 | 87.17 |
| 2025-05-21 | 86.99 |
| 2025-05-20 | 88.57 |
| 2025-05-19 | 86.49 |
| 2025-05-16 | 84.33 |
| 2025-05-15 | 84.17 |
| 2025-05-14 | 82.89 |
| 2025-05-13 | 83.89 |
| 2025-05-12 | 85.89 |
| 2025-05-09 | 81.30 |
| 2025-05-08 | 83.19 |
| 2025-05-07 | 81.54 |
| 2025-05-06 | 79.38 |
| 2025-05-05 | 83.91 |
| 2025-05-02 | 86.37 |
| 2025-05-01 | 85.33 |
| 2025-04-30 | 86.99 |
| 2025-04-29 | 86.59 |
| 2025-04-28 | 84.13 |
| 2025-04-25 | 84.33 |
| 2025-04-24 | 85.05 |
| 2025-04-23 | 87.67 |
| 2025-04-22 | 87.05 |
| 2025-04-21 | 86.95 |